Literature DB >> 12069983

Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Karidia Diallo1, Maureen Oliveira, Daniela Moisi, Bluma Brenner, Mark A Wainberg, Matthias Götte.   

Abstract

We cultured lamivudine-resistant human immunodeficiency virus type 1 (HIV-1) variants over an extended period of time in the presence of zidovudine and observed a premature reversion of the resistance-conferring M184V mutation. These data suggest that the presence of ZDV amplifies differences in replication capacity between wild-type HIV-1 and the mutant variant.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12069983      PMCID： PMC127311          DOI： 10.1128/AAC.46.7.2254-2256.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Authors:  N Shulman; A R Zolopa; D Passaro; R W Shafer; W Huang; D Katzenstein; D M Israelski; N Hellmann; C Petropoulos; J Whitcomb
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

2.  Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.

Authors:  B Masquelier; D Descamps; I Carrière; F Ferchal; G Collin; M Denayrolles; A Ruffault; B Chanzy; J Izopet; C Buffet-Janvresse; M P Schmitt; E Race; H J Fleury; J P Aboulker; P Yeni; F Brun-Vézinet
Journal:  Antivir Ther       Date:  1999

3.  Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Authors:  S Peters; M Muñoz; S Yerly; V Sanchez-Merino; C Lopez-Galindez; L Perrin; B Larder; D Cmarko; S Fakan; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

5.  The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.

Authors:  M Götte; D Arion; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Authors:  B A Larder; S D Kemp; P R Harrigan
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

7.  3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.

Authors:  B A Larder
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.

Authors:  G Tachedjian; J Mellors; H Bazmi; C Birch; J Mills
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors.

Authors:  V W Byrnes; E A Emini; W A Schleif; J H Condra; C L Schneider; W J Long; J A Wolfgang; D J Graham; L Gotlib; A J Schlabach
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Authors:  M A Wainberg; M D Miller; Y Quan; H Salomon; A S Mulato; P D Lamy; N A Margot; K E Anton; J M Cherrington
Journal:  Antivir Ther       Date:  1999
View more
  4 in total

Review 1.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.

Authors:  Jeffrey P Murry; Joanne Higgins; Timothy B Matthews; Victoria Y Huang; Koen K A Van Rompay; Niels C Pedersen; Thomas W North
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.

Authors:  Barbara A Rath; Richard A Olshen; Jerry Halpern; Thomas C Merigan
Journal:  Viruses       Date:  2012-08-07       Impact factor: 5.048

Review 4.  Reversing resistance: different routes and common themes across pathogens.

Authors:  Richard C Allen; Jan Engelstädter; Sebastian Bonhoeffer; Bruce A McDonald; Alex R Hall
Journal:  Proc Biol Sci       Date:  2017-09-27       Impact factor: 5.349
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.